Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on September 24, 2018. The report discloses a strategic partnership event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses on a corporate event rather than financial performance data.
Material Changes
On September 24, 2018, the Company entered into a distribution, license, and supply agreement with Knight Therapeutics Inc., a Canadian specialty pharmaceutical company. Key terms include:
- Granting Knight the exclusive right to commercialize Mytesi (crofelemer) in Canada and Israel.
- Mytesi is the Company's FDA-approved, first-in-class anti-secretory human prescription drug.
- Granting Knight a right of first negotiation to commercialize Mytesi and related products in specified Latin American countries.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the new agreement. The primary focus is the expansion of commercial reach for Mytesi into new international markets.
Investor Verification Checklist
- Verify the specific Latin American countries covered under the right of first negotiation.
- Review the full text of the distribution, license, and supply agreement (Exhibit 99.1) for royalty rates and milestone payments.
- Assess the impact of this partnership on Jaguar Health's future revenue projections for the Canadian and Israeli markets.